With a raft of new guidance documents, the US FDA is trying to instill order in the potentially chaotic process that some currently approved protein products will face in March 2020, while also clarifying the requirements for bringing new biosimilar products to market.
The agency released four guidance documents Dec. 11 under its Biosimilars Action Plan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?